NEWS & EVENTS

Ayala Pharmaceuticals Presents Phase 1b Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting for AL101, a Pan-Notch Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors June 4, 2018

Ayala Notches Up $17M in Financing to Push BMS Drug into Phase 2 April 10, 2018

Ayala Pharmaceuticals Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments December 6, 2017